Open Label Trial of Immunotherapy for Advanced Liver Cancer
NCT02256514
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
HCC
Liver Cirrhosis
Interventions
BIOLOGICAL:
Daily oral dose of hepcortespenlisimut-L
Sponsor
Immunitor LLC
Collaborators
[object Object]